Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Mar 26, 2010

Premium

Bio-Rad Laboratories said this week that Ted Love has been appointed to its board of directors, bringing the company back into compliance with New York Stock Exchange listing requirements.

Love will be on the board's audit committee. The NYSE requires a listed company to have three independent directors on its audit committee.

Love is the executive vice president of R&D at Onyx Pharmaceuticals. Prior to that, he was president, CEO, and a board member of Nuvelo. He will stand for election along with Bio-Rad's other board members at the company's annual meeting on April 27.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.